Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001228273 | SCV001400665 | uncertain significance | Peroxisome biogenesis disorder, complementation group 7 | 2022-09-06 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 113 of the PEX10 protein (p.Leu113Pro). This variant is present in population databases (rs757778155, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with PEX10-related conditions. ClinVar contains an entry for this variant (Variation ID: 955602). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002480749 | SCV002787790 | uncertain significance | Peroxisome biogenesis disorder 6A (Zellweger); Peroxisome biogenesis disorder 6B | 2021-12-07 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001828822 | SCV002094136 | uncertain significance | Zellweger spectrum disorders | 2020-09-13 | no assertion criteria provided | clinical testing |